Irene Paterniti Selected Research

Squamous Cell Carcinoma of Head and Neck

3/2024	Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796.
5/2023	Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC).
2/2023	Therapeutic Potential of Dimethyl Fumarate in Counteract Oral Squamous Cell Carcinoma Progression by Modulating Apoptosis, Oxidative Stress and Epithelial-Mesenchymal Transition.
12/2021	Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma.
10/2021	NLRP3 Inflammasome Inhibitor BAY-117082 Reduces Oral Squamous Cell Carcinoma Progression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Irene Paterniti Research Topics

Disease

62	Inflammation (Inflammations) 04/2024 - 08/2009
32	Spinal Cord Injuries (Spinal Cord Injury) 03/2024 - 05/2009
22	Neuroinflammatory Diseases 09/2023 - 01/2011
20	Neoplasms (Cancer) 04/2024 - 02/2018
13	Ischemia 11/2021 - 02/2010
11	Myelitis 01/2014 - 05/2009
10	Wounds and Injuries (Trauma) 08/2022 - 02/2011
10	Reperfusion Injury 11/2021 - 02/2010
8	Parkinson Disease (Parkinson's Disease) 04/2024 - 01/2012
8	Glioblastoma (Glioblastoma Multiforme) 02/2024 - 12/2020
7	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2023 - 12/2014
7	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 01/2014
6	Migraine Disorders (Migraine) 01/2024 - 02/2020
6	Pleurisy (Pleuritis) 05/2014 - 02/2010
5	Squamous Cell Carcinoma of Head and Neck 03/2024 - 10/2021
5	Pain (Aches) 01/2024 - 02/2020
5	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2023 - 04/2016
5	Brain Neoplasms (Brain Tumor) 01/2023 - 12/2020
5	Edema (Dropsy) 11/2020 - 11/2010
5	Aneurysm (Aneurysms) 01/2019 - 08/2011
5	Shock 07/2011 - 02/2010
4	Lung Injury 08/2023 - 07/2011
4	Hyperalgesia 12/2022 - 11/2010
4	Body Weight (Weight, Body) 05/2012 - 02/2010
4	Pneumonia (Pneumonitis) 10/2011 - 02/2010
4	Multiple Organ Failure (MODS) 07/2011 - 02/2010
4	Septic Shock (Toxic Shock Syndrome) 07/2011 - 02/2010
3	Glioma (Gliomas) 01/2023 - 04/2021
3	Hypersensitivity (Allergy) 09/2022 - 02/2020
3	Mouth Neoplasms (Oral Cancer) 12/2021 - 07/2021
3	Colitis 04/2016 - 01/2010
3	Necrosis 04/2016 - 10/2011
3	Brain Ischemia (Cerebral Ischemia) 01/2016 - 02/2011
3	Spinal Cord Compression 07/2013 - 04/2011
3	Brain Injuries (Brain Injury) 04/2013 - 02/2011
3	Pancreatitis 07/2012 - 05/2012
3	Periodontitis 01/2011 - 01/2010

Drug/Important Bio-Agent (IBA)

23	CytokinesIBA 01/2023 - 05/2009
14	palmidrolIBA 03/2024 - 08/2011
11	Proteins (Proteins, Gene)FDA Link 04/2024 - 05/2010
11	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2022 - 05/2009
11	3-nitrotyrosineIBA 01/2014 - 05/2009
10	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 10/2020 - 05/2009
9	CarrageenanIBA 04/2020 - 02/2010
8	LuteolinIBA 03/2024 - 07/2013
8	LigandsIBA 11/2023 - 02/2010
7	Dimethyl FumarateIBA 02/2023 - 04/2016
7	Neuroprotective AgentsIBA 01/2018 - 02/2011
7	Peroxidase (Myeloperoxidase)IBA 01/2018 - 01/2010
6	InflammasomesIBA 03/2024 - 01/2019
6	xyloglucanIBA 01/2024 - 01/2020
6	Pea ProteinsIBA 01/2024 - 05/2020
6	Prolyl OligopeptidasesIBA 08/2023 - 12/2020
6	AntioxidantsIBA 06/2022 - 07/2013
6	(4- (((2- (3- fluoro- 4- (trifluoromethyl)phenyl)- 4- methyl- 1,3- thiazol- 5- yl)methyl)sulfanyl)- 2- methylphenoxy)acetic acidIBA 07/2012 - 02/2010
6	NF-kappa B (NF-kB)IBA 07/2012 - 05/2009
5	3- (4- methylphenylsulfonyl)- 2- propenenitrileIBA 03/2024 - 11/2020
5	Phosphotransferases (Kinase)IBA 02/2024 - 02/2010
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2023 - 02/2010
5	4-phenylbutanoyl-prolylcyanopyrrolidineIBA 08/2023 - 07/2021
5	Transcription Factors (Transcription Factor)IBA 05/2023 - 05/2009
5	EnzymesIBA 01/2021 - 01/2010
5	LipopolysaccharidesIBA 01/2021 - 08/2017
5	FumaratesIBA 07/2020 - 04/2016
5	Glial Fibrillary Acidic ProteinIBA 01/2018 - 04/2013
5	co-ultraPEALutIBA 01/2016 - 07/2013
5	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 12/2014 - 02/2010
4	MelatoninIBA 03/2022 - 08/2009
4	Nerve Growth Factors (Neurotrophins)IBA 04/2021 - 04/2011
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2020 - 11/2010
4	Liver X ReceptorsIBA 01/2017 - 02/2010
4	olprinoneIBA 10/2011 - 07/2010
4	ZymosanIBA 07/2011 - 02/2010
4	NADPH Oxidases (NAD(P)H oxidase)IBA 07/2011 - 02/2011
4	acetovanillone (apocynin)IBA 03/2011 - 11/2010
4	PPAR-betaIBA 08/2010 - 02/2010
3	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2024 - 02/2020
3	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 05/2023 - 01/2012
3	Biomarkers (Surrogate Marker)IBA 02/2023 - 02/2022
3	diazonaphthalenedisulfonic acid (NDS)IBA 01/2023 - 07/2020
3	sodium propionateIBA 12/2022 - 10/2021
3	Volatile Fatty AcidsIBA 12/2022 - 10/2021
3	Therapeutic UsesIBA 12/2022 - 07/2020
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2020 - 01/2010
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2017 - 11/2010
3	DinitrobenzenesIBA 04/2016 - 01/2010
3	Fatty Acids (Saturated Fatty Acids)IBA 08/2015 - 05/2009
3	CeruletideIBA 07/2012 - 05/2012
3	Olive OilIBA 05/2012 - 08/2011
3	oleuropein aglyconeIBA 05/2012 - 08/2011
3	Mitogen-Activated Protein KinasesIBA 05/2012 - 02/2011
3	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 05/2012 - 02/2010
3	GlucocorticoidsIBA 01/2012 - 05/2009
3	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 10/2011 - 05/2010
3	Poly Adenosine Diphosphate RiboseIBA 07/2011 - 02/2010

Therapy/Procedure

19	Therapeutics 04/2024 - 02/2010
14	Laminectomy 01/2019 - 05/2009
5	Surgical Instruments (Clip) 01/2019 - 08/2011
3	Radiotherapy 02/2024 - 02/2018
3	Drug Therapy (Chemotherapy) 04/2021 - 01/2015